Neogenomics (NEO) Common Equity (2010 - 2026)

Neogenomics has reported Common Equity for 17 years, with the latest figure at $828.8 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 6.7% year-over-year to $828.8 million; the trailing twelve-month figure through Mar 2026 stood at $828.8 million (down 6.7% YoY), and the FY2025 full-year result was $836.6 million, down 7.29% from the prior year.
• Common Equity for Q1 2026 stood at $828.8 million, down from $836.6 million in the prior quarter.
• The five-year high for Common Equity was $1.1 billion in Q1 2022, with the low at $828.8 million in Q1 2026.
• Historically, Common Equity has averaged $932.1 million across 5 years, with a median of $923.4 million in 2024.
• The largest YoY upside for Common Equity was 27.41% in 2022 against a maximum downside of 10.93% in 2022.
• Neogenomics' Common Equity stood at $998.0 million in 2022, then decreased by 5.66% to $941.5 million in 2023, then declined by 4.16% to $902.3 million in 2024, then dropped by 7.29% to $836.6 million in 2025, then declined by 0.93% to $828.8 million in 2026.
• The last three Common Equity figures came in at $828.8 million (Q1 2026), $836.6 million (Q4 2025), and $838.3 million (Q3 2025), per Business Quant data.